Chemoradiotherapy versus radiotherapy in patients with stage T1-2N0M0 small cell lung cancer: a retrospective cohort study.

IF 2.8 3区医学 Q2 RESPIRATORY SYSTEM

BMC Pulmonary Medicine Pub Date : 2025-09-30 DOI:10.1186/s12890-025-03918-0

Juan Lin, Huan-Wei Liang, Yang Liu, Wei Huang, Xin-Bin Pan

{"title":"Chemoradiotherapy versus radiotherapy in patients with stage T1-2N0M0 small cell lung cancer: a retrospective cohort study.","authors":"Juan Lin, Huan-Wei Liang, Yang Liu, Wei Huang, Xin-Bin Pan","doi":"10.1186/s12890-025-03918-0","DOIUrl":null,"url":null,"abstract":"Purpose: To compare survival outcomes between chemoradiotherapy versus radiotherapy in patients with stage T1-2N0M0 small cell lung cancer (SCLC).Materials and methods: SCLC patients from the Surveillance, Epidemiology, and End Results databases between 2000 and 2020 were investigated. Kaplan-Meier survival analysis was employed to assess cancer-specific survival (CSS) and overall survival (OS).Results: Among 525 eligible patients, 371 (70.7%) received chemoradiotherapy, 64 (12.2%) underwent radiotherapy, and 90 (17.1%) received chemotherapy. While 5-year SCLC-specific mortality rates were comparable between chemoradiotherapy and radiotherapy groups (57.1% vs. 51.8%, P = 0.660), non-cancer mortality demonstrated significant reduction with chemoradiotherapy (13.3% vs. 30.2%, P = 0.004). After propensity score matching, median CSS was 27 months with chemoradiotherapy versus 26 months with radiotherapy (hazard ratio [HR] = 0.93, 95% confidence interval [CI]: 0.57-1.52; P = 0.787). Multivariable analysis confirmed radiotherapy was not an independent prognostic factor for CSS (HR = 0.85, 95% CI: 0.52-1.41; P = 0.532). Median OS was 21.5 months for chemoradiotherapy and 20 months for radiotherapy (HR = 1.11, 95% CI: 0.76-1.64; P = 0.586). Multivariable analysis confirmed radiotherapy was not an independent prognostic factor for OS (HR = 1.03, 95% CI: 0.69-1.54; P = 0.888).Conclusion: Radiotherapy demonstrates comparable survival outcomes to chemoradiotherapy in stage T1-2N0M0 SCLC patients.","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"435"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487578/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12890-025-03918-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare survival outcomes between chemoradiotherapy versus radiotherapy in patients with stage T1-2N0M0 small cell lung cancer (SCLC).

Materials and methods: SCLC patients from the Surveillance, Epidemiology, and End Results databases between 2000 and 2020 were investigated. Kaplan-Meier survival analysis was employed to assess cancer-specific survival (CSS) and overall survival (OS).

Results: Among 525 eligible patients, 371 (70.7%) received chemoradiotherapy, 64 (12.2%) underwent radiotherapy, and 90 (17.1%) received chemotherapy. While 5-year SCLC-specific mortality rates were comparable between chemoradiotherapy and radiotherapy groups (57.1% vs. 51.8%, P = 0.660), non-cancer mortality demonstrated significant reduction with chemoradiotherapy (13.3% vs. 30.2%, P = 0.004). After propensity score matching, median CSS was 27 months with chemoradiotherapy versus 26 months with radiotherapy (hazard ratio [HR] = 0.93, 95% confidence interval [CI]: 0.57-1.52; P = 0.787). Multivariable analysis confirmed radiotherapy was not an independent prognostic factor for CSS (HR = 0.85, 95% CI: 0.52-1.41; P = 0.532). Median OS was 21.5 months for chemoradiotherapy and 20 months for radiotherapy (HR = 1.11, 95% CI: 0.76-1.64; P = 0.586). Multivariable analysis confirmed radiotherapy was not an independent prognostic factor for OS (HR = 1.03, 95% CI: 0.69-1.54; P = 0.888).

Conclusion: Radiotherapy demonstrates comparable survival outcomes to chemoradiotherapy in stage T1-2N0M0 SCLC patients.

查看原文本刊更多论文

T1-2N0M0期小细胞肺癌患者放化疗与放疗：一项回顾性队列研究

目的：比较T1-2N0M0期小细胞肺癌（SCLC）患者放化疗与放疗的生存结果。材料和方法：对2000年至2020年监测、流行病学和最终结果数据库中的SCLC患者进行调查。采用Kaplan-Meier生存分析评估癌症特异性生存（CSS）和总生存（OS）。结果：525例符合条件的患者中，371例（70.7%）接受放化疗，64例（12.2%）接受放疗，90例（17.1%）接受化疗。放化疗组和放疗组的5年sclc特异性死亡率相当（57.1%比51.8%,P = 0.660），放化疗组的非癌症死亡率显著降低（13.3%比30.2%,P = 0.004）。倾向评分匹配后，中位CSS分别为放化疗27个月和放疗26个月（风险比[HR] = 0.93, 95%可信区间[CI]: 0.57-1.52; P = 0.787）。多变量分析证实放疗不是CSS的独立预后因素（HR = 0.85, 95% CI: 0.52-1.41; P = 0.532）。放化疗的中位OS为21.5个月，放疗的中位OS为20个月（HR = 1.11, 95% CI: 0.76-1.64; P = 0.586）。多变量分析证实放疗不是OS的独立预后因素（HR = 1.03, 95% CI: 0.69-1.54; P = 0.888）。结论：放疗在T1-2N0M0期SCLC患者的生存结果与放化疗相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Pulmonary Medicine RESPIRATORY SYSTEM-

CiteScore

4.40

自引率

3.20%

发文量

423

审稿时长

6-12 weeks

期刊介绍： BMC Pulmonary Medicine is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.